Track Standard BioTools Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Standard BioTools Inc. Common Stock LAB Open Standard BioTools Inc. Common Stock in new tab

0.9891 USD
EPS
-0.13
P/B
0.68
ROE
-9.86
Beta
1.31
Key Metrics
Earnings dateAug. 10, 2026
EPS-0.13
Book Value1.44
Price to Book0.68
Debt/Equity5.26
% Insiders1.502%
Growth
Revenue Growth0.05%
Estimates
Forward P/E-98.48
Forward EPS-0.01

DCF Valuation

Tweak assumptions to recompute fair value for Standard BioTools Inc. Common Stock (LAB)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Standard BioTools Inc. Common Stock Analysis (LAB)

United States Health Care Stock

Is Standard BioTools Inc. Common Stock a good investment? Standard BioTools Inc. Common Stock (LAB) is currently trading at 0.9891 USD.

Earnings Schedule: Standard BioTools Inc. Common Stock is expected to release its next earnings report on Aug. 10, 2026. The market consensus estimate for Forward EPS is -0.01.

Investor FAQ

Does Standard BioTools Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Standard BioTools Inc. Common Stock?

Standard BioTools Inc. Common Stock is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Aug. 10, 2026. The company currently has a trailing EPS of -0.13.

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion